"Enter"a basıp içeriğe geçin

Prematüre Retinopatisi

Loading

Prematurity of Retinopathy

Yazarlar: Muhammed Atıf İNCE1, Gaffari TUNÇ2

Corresponding author
1Muhammed Atıf İnce, Sivas Cumhuriyet Üniversitesi Tıp Fakültesi Dönem 3, Sivas, Türkiye
E-mail: atif.ince@hotmail.com
Other authors
2Sivas Cumhuriyet Üniversitesi Tıp Fakültesi Çocuk Sağlığı ve Hastalıkları Anabilim Dalı, Yenidoğan Bilim Dalı, Sivas, Türkiye

ÖZET

Prematüre Retinopatisi (PR), çocukluk çağında bilateral körlüğün önde gelen nedenlerinden biridir. PR’nin klinik spektrumu spontan gerilemeden bilateral retina dekolmanına ve total körlüğe kadar değişmektedir. En önemli risk faktörleri prematüre ve düşük doğum ağırlıklı bebeklerdir. Oksijen toksisitesi ve göreceli hipoksi, PR gelişimine katkıda bulunabilir. Doğum ağırlığı <1500 g veya gestasyonel yaş ≤32 hafta ve doğum ağırlığı> 1500 g veya gestasyonel yaşı> 32 hafta üzerinde olup klinik seyri stabil olmayan bebeklere prematüre retinopatisi taranmalıdır. PR tedavi seçenekleri lazer fotokoagülasyonu, anti-vasküler endotelyal büyüme faktörü içeren ilaçların kullanılması ve cerrahi operasyondur.

Anahtar Kelimeler: Düşük doğum ağırlıklı bebekler, prematür bebek, retinopati, tedavi.

ABSTRACT

Retinopathy of Prematurity (ROP) is one of the leading causes of bilateral blindness in childhood. The clinical spectrum of ROP varies from spontaneous regression to bilateral retinal detachment and total blindness. The most important risk factors are prematurity and low birth weight babies. Oxygen toxicity and relative hypoxia can contribute to the development of ROP. Birth weight (BW)<1500 g or gestational age ≤32 weeks and babies with an unstable clinical course and those that BW> 1500 g or GA> 32 weeks should be screened. Treatment options for premature retinopathy are laser photocoagulation, the use of drugs containing anti-vascular endothelial growth factor and surgical operation.

Keywords: Low birth weight babies, premature infant, retinopathy, treatment.

How to Cite (APA 7)

Ince, M. A., Tunc, G. (2021). Prematüre Retinopatisi. Health Sciences Student Journal, 1(1), 24-29. https://healthssj.com/premature-retinopatisi/

KAYNAKÇA/REFERENCES

1.       Terry, T. L. (1942). Extreme prematurity and fibroblastic overgrowth of persistent vascular sheath behind each crystalline lens. I. Preliminary report. American Journal of Ophthalmology, 25(2), 203–204. https://doi.org/10.1016/S0002-394(42)92088-9

2.       Tasman, W., Patz, A., McNamara, J. A., Kaiser, R. S., Trese, M. T., & Smith, B. T. (2006). Retinopathy of prematurity: The life of a lifetime disease. American Journal of Ophthalmology, 141(1), 167–174. https://doi.org/10.1016/j.ajo.2005.07.034

3.       Steinkuller, P. G., Du, L., Gilbert, C., Foster, A., Collins, M. L., & Coats, D. K. (1999). Childhood blindness. Journal of AAPOS : The Official Publication of the American Association for Pediatric Ophthalmology and Strabismus / American Association for Pediatric Ophthalmology and Strabismus, 3(1), 26–32. https://doi.org/10.1016/S1091-8531(99)70091-1

4.       Childhood blindness in the context of VISION                 2020–the right to sight – PubMed. (n.d.). Retrieved December 23, 2020, from https://pubmed.ncbi.nlm.nih.gov/11285667/

5.       Koç, E., Bas, A. Y., Özdek, Ş., Ovalı, F., Başmak, H., TOD ROP  Komisyonu, TND ROP Çalışma Grubu, (2016). Türkiye Prematüre Retinopatisi Rehberi.

6.       Bas, A. Y., Demirel, N., Koc, E., Ulubas Isik, Di., Hirfanoglu, I. M., & Tunc, T. (2018). Incidence, risk factors and severity of retinopathy of prematurity in Turkey (TR-ROP study): A prospective, multicentre study in 69 neonatal intensive care units. British Journal of Ophthalmology, 102(12), 1711–1716. https://doi.org/10.1136/bjophthalmol-2017-311789

7.       Askie, L. M., Henderson-Smart, D. J., Irwig, L., & Simpson, J. M. (2003). Oxygen-Saturation Targets and Outcomes in Extremely Preterm Infants. New England Journal of Medicine, 349(10), 959–967. https://doi.org/10.1056/nejmoa023080

8.       Kinsey, V. E., Arnold, H. J., & Kalina, R. E. (1977). PaO2 levels and retrolental fibroplasia: A report of the cooperative study. Pediatrics, 60(5), 655–668. https://europepmc.org/article/med/578921

9.       Wallace, D. K., Kylstra, J. A., Phillips, S. J., & Hall, J. G. (2000). Poor postnatal weight gain: A risk factor for severe retinopathy of prematurity. Journal of AAPOS, 4(6), 343–347. https://doi.org/10.1067/mpa.2000.110342

10.     Englert, J. A., Saunders, R. A., Purohit, D., Hulsey, T. C., & Ebeling, M. (2001). The effect of anemia on retinopathy of prematurity in extremely low birth weight infants. Journal of Perinatology, 21(1), 21–26. https://doi.org/10.1038/sj.jp.7200511

11.     Uslu, S., & Bülbül, A. (2011). Neonatoloji bakış açısı ile prematüre retinopatisi. Şişli Etfal Hastanesi Tıp Bülteni, 45(4), 142–152. https://app.trdizin.gov.tr/makale/TVRJNE9EWXlNZz09/neonatoloji-bakis-cisi-ile-premature-retinopatisi

12.     ARSAN, S. (2004). Prematüre Retinopatisi. Türkiye Klinikleri Pediatri Özel Dergisi, 2(4), 382–386. https://www.turkiyeklinikleri.com/article/tr-premature-retinopatisi-35472.html

13. Phelps, D. L. (2001). Retinopathy of Prematurity: History, Classification, and Pathophysiology. NeoReviews, 2(7), 153e – 166. https://doi.org/10.1542/neo.2-7-e153

14.     McColm, Mol Vis 2004; 10:512-520. (n.d.). Retrieved December 23, 2020, from http://www.molvis.org/molvis/v10/a63/

15.     Smith, L. E. H. (2004). Pathogenesis of retinopathy of prematurity. Growth Hormone and IGF Research, 14(SUPPL. A). https://doi.org/10.1016/j.ghir.2004.03.030

16.     Hellström, A., Engström, E., Hård, A. L., Albertsson-Wikland, K., Carlsson, B., Niklasson, A., Löfqvist, C., Svensson, E., Holm, S., Ewald, U., Holmström, G., & Smith, L. E. H. (2003). Postnatal Serum Insulin-Like Growth Factor I Deficiency is Associated with Retinopathy of Prematurity and Other Complications of Premature Birth. Pediatrics, 112(5), 1016–1020. https://doi.org/10.1542/peds.112.5.1016

17.     Quinn, G. E. (2005). The international classification of retinopathy of prematurity revisited: An international committee for the classification of retinopathy of prematurity. In Archives of Ophthalmology (Vol. 123, Issue 7, pp. 991–999). American Medical Association. https://doi.org/10.1001/archopht.123.7.991

18.     Good, W. V., Hardy, R. J., Dobson, V., Palmer, E. A., Phelps, D. L., Quintos, M., Tung, B., Madan, A., Ball, M. B., Hartsell, P. N., Inguillo, D., Gaynon, M., Alcorn, D., Ornitz, D., Gancasz, J., Durand, D., Slagle, T., Smith, G., Shapiro, M., … Barr, C. (2006). The early treatment for retinopathy of prematurity study: Structural findings at age 2 years. British Journal of Ophthalmology, 90(11), 1378–1382. https://doi.org/10.1136/bjo.2006.098582

19.     Multicenter Trial of Cryotherapy for Retinopathy of Prematurity: Three-Month Outcome. (1990). Archives of Ophthalmology, 108(2), 195–204. https://doi.org/10.1001/archopht.1990.01070040047029

20.     Screening Examination of Premature Infants for Retinopathy of Prematurity – 2013 – American Academy of Ophthalmology. (n.d.). Retrieved December 24, 2020, from https://www.aao.org/clinical-statement/screening-examination-of-premature-infants-retinop

21.     Reynolds, J. D., Hardy, R. J., Kennedy, K. A., Spencer, R., van Heuven, W. A. J., & Fielder, A. R. (1998). Lack of Efficacy of Light Reduction in Preventing Retinopathy of Prematurity. New England Journal of Medicine, 338(22), 1572–1576. https://doi.org/10.1056/nejm199805283382202

22.     Paysse, E. A., Miller, A., Brady McCreery, K. M., & Coats, D. K. (2002). Acquired cataracts after diode laser photocoagulation for threshold retinopathy of prematurity. Ophthalmology, 109(9), 1662–1665. https://doi.org/10.1016/S0161-6420(02)01169-7

23.     Coats, D. K., Miller, A. M., Brady McCreery, K. M., Holz, E. R., & Paysse, E. A. (2004). Involution of threshold retinopathy of prematurity after diode laser photocoagulation. Ophthalmology, 111(10), 894–1898. https://doi.org/10.1016/j.ophtha.2004.02.005

24.     Micieli, J. A., Surkont, M., & Smith, A. F. (2009). A Systematic Analysis of the Off-Label Use of Bevacizumab for Severe Retinopathy of Prematurity. American Journal of Ophthalmology, 148(4). https://doi.org/10.1016/j.ajo.2009.05.031

25.     Castellanos, M. A. M., Schwartz, S., García-Aguirre, G., & Quiroz-Mercado, H. (2013). Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity. British Journal of Ophthalmology, 97(7), 816–819. https://doi.org/10.1136/bjophthalmol-2012-302276

26.     Koç, E., Yağmur Baş, A., Özdek, Ş., Ovalı, F., & Başmak, H. (2018). Turkish neonatal and Turkish ophthalmology societies consensus guideline on the retinopathy of prematurity. Turk Pediatri Arsivi, 53, S151–S160. https://doi.org/10.5152/TurkPediatriArs.2018.0181